Fatal Poisoning in Methadone and Buprenorphine Treated Patients - Are there Differences?

Background: Some recent studies have suggested a lower risk of fatal intoxications in drug-dependent patients under buprenorphine compared to methadone treatment. Methods: Epidemiological reference data for the Munich region suggest that in 2003 approximately 10 % of all substitution patients were treated with buprenorphine, and 87 % with methadone. We studied the proportion of patients under methadone and buprenorphine substitution among drug-related deaths. Data from forensic post-mortem and toxicological analysis were analyzed. Results: Data indicate that in 96 (35 %) of all 272 so-called drug deaths, methadone was involved compared to a single case of buprenorphine, possibly indicating a relatively better risk profile of buprenorphine. Discussion: More prospective studies are necessary to assess the risk of fatal intoxications under different substitution regimens.

References

• 1 Amass L, Kamien J B, Mikulich S K. Efficacy of daily and alternate-day dosing regimens with the combination of buprenorphine-naloxone tablet.  Drug Alcohol Depend. 2000;  58 143-152
• 2 Auriacombe M, Fatseas M, Dubernet J, Daulouede J P, Tignol J. French field experience with buprenorphine.  Am J Addict. 2001;  13 (Suppl. 1) S17-28
• 3 Barnett P G, Rodgers J H, Bloch D A. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence.  Addiction. 2001;  96 683-690
• 4 Bickel W K, Amass L, Crean J P, Badger G J. Buprenorphine dosing every 1,2, or 3 days in opioid-dependent patients.  Psychopharmacology. 1999;  146 111-118
• 5 Brugal M T, Domingo-Salvany A, Puig R, Barrio G, Garcia de Olalla P, de la Fuente L. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain.  Addiction. 2005;  100 981-989
• 6 Bryant W K, Galea S, Tracy M. et al . Overdose deaths attributed to methadone and heroin in New York City, 1990-1998.  Addiction. 2004;  99 846-854
• 7 Bühringer G, Kröger C, Küfner H, Lieb R, Schütz C, Soyka M, Wittchen H -U. Substance abuse research network ASAT: allocating substance abuse to patient heterogeneity (in German).  Suchtmed. 2004;  6 7-13
• 8 Davids E, Gastpar M. Buprenorphine in the treatment of opiod dependence.  Eur Neuropsychopharmacology. 2004;  14 209-216
• 9 Heinemann A, Andresen H, Raschke P. Methadone-associated mortality among opiate users in Hamburg/Germany 1990-2001 (in German).  Suchtmed. 2005;  7 27-32
• 10 Kagerer S, Backmund M, Walcher S, Soyka M. Substitution with Buprenorphine and Driving Ability - Results from an experimental study (in German).  Suchtmed. 2002;  4 17-24
• 11 Kintz P. A new series of 13 buprenorphine-related deaths.  Clin Biochem. 2002;  35 513-516
• 12 Penning R, von Meyer  L, Sachs H, Zinka B. Methadone-associated drug deaths in 2002 and 2003 - data of the Institute of Legal Medicine Munich (in German).  Suchtmed. 2005;  7 19-25
• 13 Pirnay S, Borron S W, Giudicelli C P, Torneau J, Baud F J, Ricordel I. A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths.  Addiction. 2004;  99 978-988
• 14 Robinson G M. Dukes PD, Robinson BJ, Cooke RR, Mahoney GN. The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand.  Drug Alcohol Depend. 1993;  33 81-86
• 15 Schifano F, Corkery J, Gilvarry E, Deluca P, Oyefeso A, Ghodse A H. Buprenorphine mortality, Seizures and prescription in the UK, 1980-2002.  Hum Psychopharmacol Clin Exp. 2005;  20 343-348
• 16 Shah N, Lathrop S L, Landen M G. Unintentional methadone-related overdose death in New Mexico (USA) and implications for surveillance, 1998-2002.  Addiction. 2005;  100 176-188
• 17 Soyka M, Horak M, Dittert S, Kagerer S. Less driving impairment on buprenorphine than methadone in drug dependent patients.  J Neuropsychiatry Clin Neurosci. 2001;  13 527-528
• 18 Soyka M, Hock B, Kagerer S, Lehnert R, Limmer C, Kuefner H. Less Impairment on one portion of adriving-relevant psychomotor battery in buprenorphine-maintained than in methadone-maintained patients: results of a randomized clinical trial.  J Clin Psychopharmacol. 2005;  25 490-493
• 19 Stempel J. Illegal drugs - numbers and facts (in German.) Deutsche Hauptstelle gegen die Suchtgefahren (Ed): Jahrbuch Sucht 2005. Geesthacht; Neuland Verlag 69-82
• 20 Strain E C, Preston K L, Liebson I A, Bigelow G E. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.  J Pharmacol Exp Ther. 1995;  261 985-993
• 21 Strain E C, Preston K I, Liebson I A, Bigelow G E. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.  J Pharmacol Exp Ther. 1995;  272 628-638
• 22 Vormfelde S V, Poser Z. Death attributed to Methadone.  Pharmacopsychiatry. 2001;  34 217-222
• 23 Wittchen H -U, Apelt S M, Christl B, Hagenau K A, Groß A, Klotsche J, Soyka M. The practice of supply in the substitution therapy for opiate addicts (COBRA) (in German).  Suchtmed. 2004;  6 80-87
• 24 Wittchen H -U, Apelt S, Soyka M, Bühringer G, Gastpar M, Backmund M, Gölz J, Kraus M R, Tretter F, Klotsche J, Siegert J, Pittrow D, Soyka M. Buprenorphine and methadone in the treatment of opioid dependence: methods and design of the COBRA study.  Int J Meth Psychiatric Res. 2005;  14 14-28